Phathom Pharmaceuticals, Inc. Interest Expense (Operating)

Interest Expense (Operating) of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Interest Expense (Operating) growth rates and interactive chart.


Highlights and Quick Summary

  • Interest Expense (Operating) for the quarter ending June 29, 2021 was $1.26 Million (a -1.26% decrease compared to previous quarter)
  • Year-over-year quarterly Interest Expense (Operating) decreased by -2.33%
  • Annual Interest Expense (Operating) for 2020 was $4.58 Million (a 9.67% increase from previous year)
  • Annual Interest Expense (Operating) for 2019 was $4.18 Million (a 32030.77% increase from previous year)
  • Twelve month Interest Expense (Operating) ending June 29, 2021 was $5.11 Million (a -0.12% decrease compared to previous quarter)
  • Twelve month trailing Interest Expense (Operating) increased by 18.15% year-over-year
Trailing Interest Expense (Operating) for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$5.11 Million $5.12 Million $4.58 Million $4.33 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Interest Expense (Operating) of Phathom Pharmaceuticals, Inc.

Most recent Interest Expense (Operating)of PHAT including historical data for past 10 years.

Interactive Chart of Interest Expense (Operating) of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Interest Expense (Operating) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $1.26 $1.27
2020 $1.3 $1.29 $1.26 $0.74 $4.58
2019 $1.04 $4.18
2018 $0.01

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.